Selecta Biosciences (SELB) Downgraded to Hold at Zacks Investment Research

Zacks Investment Research cut shares of Selecta Biosciences (NASDAQ:SELB) from a buy rating to a hold rating in a research note released on Thursday.

According to Zacks, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. “

A number of other equities analysts also recently weighed in on the stock. UBS Group set a $6.00 price target on shares of Selecta Biosciences and gave the stock a hold rating in a report on Friday, November 9th. Mizuho restated a buy rating and issued a $30.00 price objective on shares of Selecta Biosciences in a research note on Monday, November 5th. BidaskClub cut Selecta Biosciences from a hold rating to a sell rating in a research note on Saturday, October 27th. Janney Montgomery Scott restated a buy rating on shares of Selecta Biosciences in a research note on Tuesday, October 23rd. Finally, Stifel Nicolaus restated a buy rating on shares of Selecta Biosciences in a research note on Tuesday, October 23rd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $23.21.

Shares of NASDAQ:SELB opened at $2.39 on Thursday. The stock has a market capitalization of $59.45 million, a P/E ratio of -0.75 and a beta of 2.62. Selecta Biosciences has a fifty-two week low of $2.28 and a fifty-two week high of $16.55.

Selecta Biosciences (NASDAQ:SELB) last issued its quarterly earnings results on Thursday, November 8th. The company reported ($0.71) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.79) by $0.08. As a group, analysts predict that Selecta Biosciences will post -2.92 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Selecta Biosciences by 1.5% during the third quarter. BlackRock Inc. now owns 897,480 shares of the company’s stock valued at $13,956,000 after buying an additional 12,916 shares during the period. Vanguard Group Inc increased its position in shares of Selecta Biosciences by 1.1% in the third quarter. Vanguard Group Inc now owns 655,771 shares of the company’s stock worth $10,197,000 after purchasing an additional 6,859 shares during the last quarter. Artal Group S.A. increased its position in shares of Selecta Biosciences by 12.3% in the third quarter. Artal Group S.A. now owns 561,540 shares of the company’s stock worth $8,732,000 after purchasing an additional 61,540 shares during the last quarter. Man Group plc increased its position in shares of Selecta Biosciences by 139.1% in the third quarter. Man Group plc now owns 257,315 shares of the company’s stock worth $4,001,000 after purchasing an additional 149,685 shares during the last quarter. Finally, Northern Trust Corp boosted its stake in Selecta Biosciences by 11.9% in the second quarter. Northern Trust Corp now owns 156,708 shares of the company’s stock worth $2,076,000 after buying an additional 16,615 shares in the last quarter. Hedge funds and other institutional investors own 51.04% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes synthetic vaccine particles (SPV)-enabled enzyme, oncology, and gene therapies. The company's lead product is SEL-212 that in Phase II clinical trial to treat severe gout patients and resolve their symptoms, including flares and gouty arthritis.

Read More: What are the reasons investors use put options?

Get a free copy of the Zacks research report on Selecta Biosciences (SELB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Selecta Biosciences (NASDAQ:SELB)

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply